Comparaison des Doses d'Aspirine pour la Prévention de la Prééclampsie dans les Grossesses à Risque Élevé

This study focuses on finding the best dose of Aspirin to help prevent pre-eclampsia in pregnant women who are at high risk for this condition. Pre-eclampsia is a serious condition that can affect both the mother and the baby, potentially leading to complications during pregnancy. It occurs in 5-7% of all pregnancies and can be life-threatening. Aspirin is known to help prevent pre-eclampsia by improving blood flow to the placenta and reducing inflammation and blood clot formation. This study aims to compare two different doses of Aspirin, 75mg and 150mg, to see which is more effective in the Pakistani population, as different guidelines exist on the appropriate dose for prevention of pre-eclampsia. Participants in this study will take either 75mg or 150mg of Aspirin daily from early in their pregnancy, starting at 12 weeks. Researchers will monitor the participants to see if they develop pre-eclampsia, and if so, whether it occurs early or later in the pregnancy. The outcomes will be measured by checking whether pre-eclampsia develops before or after 34 weeks of pregnancy. The study will help determine if a higher dose of Aspirin is more effective in preventing pre-eclampsia, potentially leading to improved care for pregnant women at risk of this condition. The main focus is on assessing whether the benefits of preventing pre-eclampsia outweigh any potential side effects of taking a higher dose of Aspirin.